Review of epidemiology, diagnosis, control, therapeutics and vaccine development for Crimean-Congo hemorrhagic fever
Author(s): Faizan Q Siddiqui, Ghazala Parveen and Shahzad hussain
Abstract: Crimean-Congo Hemorrhagic Fever (CCHF), among the high-priority pathogens because of its high case fatality rate and its potential for nosocomial outbreaks and the subsequent difficulties in treatment and prevention. For the last four decades, the virus has repeatedly caused an endemic in many parts of the world including Pakistan, Iran and India. Though this virus is responsible for relatively low numbers of human casualties, it is up to 80% fatal in the clinically infected patients. The availability of present diagnostic techniques is not enough for timely rescue of CCHF infected patients. The progressive work for the development of new rapid specific and reliable diagnostic tests is the need of time for the infected patient. At present Ribavirin drug is available to the clinicians as recommended therapeutic intervention. The efforts to include the other drugs like favipiravir may also be continued for its clinical efficacy and safety. Currently no safe and effective vaccine is available either for human or animal use that can prevent this disease. The development of vaccines in line with the requirement of Targeted Product Profile (TPP) as per the standards of Food and Drug Administration (FDA) is essentially needed. We discuss the techniques used in the preparation of different vaccines concerning their success and failures. In this review, we also discuss epidemiology, diagnosis, treatment and prevention in the light of recent global advances.
Faizan Q Siddiqui, Ghazala Parveen, Shahzad hussain. Review of epidemiology, diagnosis, control, therapeutics and vaccine development for Crimean-Congo hemorrhagic fever. Int J Adv Biochem Res 2018;2(1):01-05. DOI: 10.33545/26174693.2018.v2.i1a.7